Skip to main content
Top
Published in: BMC Infectious Diseases 1/2005

Open Access 01-12-2005 | Research article

A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis

Authors: Maureen Morgan, Shriprakash Kalantri, Laura Flores, Madhukar Pai

Published in: BMC Infectious Diseases | Issue 1/2005

Login to get access

Abstract

Background

Mycobacterium tuberculosis is a leading cause of death worldwide. In multi-drug resistant tuberculosis (MDR-TB) infectiousness is frequently prolonged, jeopardizing efforts to control TB. The conventional tuberculosis drug susceptibility tests are sensitive and specific, but they are not rapid. The INNO-LiPA Rif. TB ® (LiPA) is a commercial line probe assay designed to rapidly detect rifampicin resistance, a marker of MDR-TB. Although LiPA has shown promising results, its overall accuracy has not been systematically evaluated.

Methods

We did a systematic review and meta-analysis to evaluate the accuracy of LiPA for the detection of rifampicin-resistant tuberculosis among culture isolates and clinical specimens. We searched Medline, Embase, Web of Science, BIOSIS, and Google Scholar, and contacted authors, experts and the manufacturer. Fifteen studies met our inclusion criteria. Of these, 11 studies used culture isolates, one used clinical specimens, and three used both. We used a summary receiver operating characteristic (SROC) curve and Q* index to perform meta-analysis and summarize diagnostic accuracy.

Results

Twelve of 14 studies that applied LiPA to isolates had sensitivity greater than 95%, and 12 of 14 had specificity of 100%. The four studies that applied LiPA directly to clinical specimens had 100% specificity, and sensitivity that ranged between 80% and 100%. The SROC curve had an area of 0.99 and Q* of 0.97.

Conclusion

LiPA is a highly sensitive and specific test for the detection of rifampicin resistance in culture isolates. The test appears to have relatively lower sensitivity when used directly on clinical specimens. More evidence is needed before LiPA can be used to detect MDR-TB among populations at risk in clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance: Anti-Tuberculosis drug resistance in the world, report number 2. 2004, Geneva, : -. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance: Anti-Tuberculosis drug resistance in the world, report number 2. 2004, Geneva, : -.
2.
go back to reference Heifets LB, Cangelosi GA: Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis. 1999, 3: 564-581.PubMed Heifets LB, Cangelosi GA: Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis. 1999, 3: 564-581.PubMed
3.
go back to reference Hirano K, Abe C, Takahashi M: Mutations in the rpo B gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay. J Clin Microbiol. 1999, 37: 2663-2666.PubMedPubMedCentral Hirano K, Abe C, Takahashi M: Mutations in the rpo B gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay. J Clin Microbiol. 1999, 37: 2663-2666.PubMedPubMedCentral
4.
go back to reference Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A: Characterization of rpo B mutations in Rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol. 2002, 40: 4435-4438. 10.1128/JCM.40.12.4435-4438.2002.CrossRefPubMedPubMedCentral Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A: Characterization of rpo B mutations in Rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol. 2002, 40: 4435-4438. 10.1128/JCM.40.12.4435-4438.2002.CrossRefPubMedPubMedCentral
5.
go back to reference Ahmad S, Mokaddas E, Fares E: Characterization of rpo B mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis. 2002, 44: 245-252. 10.1016/S0732-8893(02)00457-1.CrossRefPubMed Ahmad S, Mokaddas E, Fares E: Characterization of rpo B mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis. 2002, 44: 245-252. 10.1016/S0732-8893(02)00457-1.CrossRefPubMed
6.
go back to reference Drobniewski FA, Wilson SM: The rapid diagnosis of isoniazid and rifampin resistance in Mycobacterium tuberculosis – a molecular story. J Med Microbiol. 1998, 47: 189-196.CrossRefPubMed Drobniewski FA, Wilson SM: The rapid diagnosis of isoniazid and rifampin resistance in Mycobacterium tuberculosis – a molecular story. J Med Microbiol. 1998, 47: 189-196.CrossRefPubMed
7.
go back to reference Rossau R, Traore H, De Beenhouwer H, Mijs W, Jannes G, De Rijk P, Portaels F: Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother. 1997, 41: 2093-2098.PubMedPubMedCentral Rossau R, Traore H, De Beenhouwer H, Mijs W, Jannes G, De Rijk P, Portaels F: Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother. 1997, 41: 2093-2098.PubMedPubMedCentral
8.
go back to reference De Beenhouwer H, Lhiang Z, Jannes G, Mijs W, Machtelinckx L, Rossau R, Traore H, Portaels F: Rapid detection of Rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber Lung Dis. 1995, 76: 425-430. 10.1016/0962-8479(95)90009-8.CrossRefPubMed De Beenhouwer H, Lhiang Z, Jannes G, Mijs W, Machtelinckx L, Rossau R, Traore H, Portaels F: Rapid detection of Rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber Lung Dis. 1995, 76: 425-430. 10.1016/0962-8479(95)90009-8.CrossRefPubMed
9.
go back to reference De Oliveira M, Rocha A, Oelemann M, Gomes H, Fonseca L, Werneck-Barreto A, Valim A, Rossetti M, Rossau R, Mijs W, Vanderborght B, Suffys P: Rapid detection of resistance against Rifampicin in isolates of Mycobacterium tuberculosis from Brazilian patients using a reverse-phase hybridization assay. J Microbiol Methods. 2003, 53: 335-342. 10.1016/S0167-7012(02)00253-1.CrossRefPubMed De Oliveira M, Rocha A, Oelemann M, Gomes H, Fonseca L, Werneck-Barreto A, Valim A, Rossetti M, Rossau R, Mijs W, Vanderborght B, Suffys P: Rapid detection of resistance against Rifampicin in isolates of Mycobacterium tuberculosis from Brazilian patients using a reverse-phase hybridization assay. J Microbiol Methods. 2003, 53: 335-342. 10.1016/S0167-7012(02)00253-1.CrossRefPubMed
10.
go back to reference Gamboa F, Cardona PJ, Manterola JM, Lonca J, Matas L, Padilla E, Manzano JR, Ausina V: Evaluation of a commercial probe assay for detection of rifampin resistance in Mycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples. Eur J Clin Microbiol Infect Dis. 1998, 17: 189-192.PubMed Gamboa F, Cardona PJ, Manterola JM, Lonca J, Matas L, Padilla E, Manzano JR, Ausina V: Evaluation of a commercial probe assay for detection of rifampin resistance in Mycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples. Eur J Clin Microbiol Infect Dis. 1998, 17: 189-192.PubMed
11.
go back to reference Johansen I, Lundgren B, Sosnovskaja A, Thomsen V: Direct detection of multidrug-resistant Mycobacterium tuberculosis in clinical specimens in low- and high-incidence countries by line probe assay. J Clin Microbiol. 2003, 41: 4454-4456. 10.1128/JCM.41.9.4454-4456.2003.CrossRefPubMedPubMedCentral Johansen I, Lundgren B, Sosnovskaja A, Thomsen V: Direct detection of multidrug-resistant Mycobacterium tuberculosis in clinical specimens in low- and high-incidence countries by line probe assay. J Clin Microbiol. 2003, 41: 4454-4456. 10.1128/JCM.41.9.4454-4456.2003.CrossRefPubMedPubMedCentral
12.
go back to reference Jureen P, Werngren J, Hoffner S: Evaluation of the line probe assay (LiPA) for rapid detection of Rifampicin resistance in Mycobacterium tuberculosis. Tuberculosis. 2004, 84: 311-316. 10.1016/j.tube.2003.12.001.CrossRefPubMed Jureen P, Werngren J, Hoffner S: Evaluation of the line probe assay (LiPA) for rapid detection of Rifampicin resistance in Mycobacterium tuberculosis. Tuberculosis. 2004, 84: 311-316. 10.1016/j.tube.2003.12.001.CrossRefPubMed
13.
go back to reference Lemus D, Martin A, Montoro E, Portaels F, Palomino J: Rapid alternative methods for detection of Rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2004, 54: 130-133. 10.1093/jac/dkh320.CrossRefPubMed Lemus D, Martin A, Montoro E, Portaels F, Palomino J: Rapid alternative methods for detection of Rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2004, 54: 130-133. 10.1093/jac/dkh320.CrossRefPubMed
14.
go back to reference Sintchenko V, Chew W, Jelfs P, Gilbert G: Mutations in rpo B gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology. 1999, 31: 257-260. 10.1080/003130299105089.CrossRefPubMed Sintchenko V, Chew W, Jelfs P, Gilbert G: Mutations in rpo B gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology. 1999, 31: 257-260. 10.1080/003130299105089.CrossRefPubMed
15.
go back to reference Somoskovi A, Song Q, Mester J, Tanner C, Hale Y, Parsons L, Salfinger M: Use of molecular methods to identify the Mycobacterium tuberculosis complex (MTBC) and other mycobacterial species and to detect rifampin resistance in MTBC isolates following growth detection with BACTEC MGIT 960 System. J Clin Microbiol. 2003, 41: 2822-2826. 10.1128/JCM.41.7.2822-2826.2003.CrossRefPubMedPubMedCentral Somoskovi A, Song Q, Mester J, Tanner C, Hale Y, Parsons L, Salfinger M: Use of molecular methods to identify the Mycobacterium tuberculosis complex (MTBC) and other mycobacterial species and to detect rifampin resistance in MTBC isolates following growth detection with BACTEC MGIT 960 System. J Clin Microbiol. 2003, 41: 2822-2826. 10.1128/JCM.41.7.2822-2826.2003.CrossRefPubMedPubMedCentral
16.
go back to reference Gamboa F, Cardona PJ, Manterola JM, Lonca J, Matas L, Padilla E, Manzano JR, Ausina V: Correlation of mutations detected by INNO-LiPA with levels of Rifampicin resistance in Mycobacterium tuberculosis. Indian J Med Res. 2004, 120: 100-105. Gamboa F, Cardona PJ, Manterola JM, Lonca J, Matas L, Padilla E, Manzano JR, Ausina V: Correlation of mutations detected by INNO-LiPA with levels of Rifampicin resistance in Mycobacterium tuberculosis. Indian J Med Res. 2004, 120: 100-105.
17.
go back to reference Tracevska T, Jansone I, Broka L, Marga O, Baumanis V: Mutations in the rpo B and katG genes leading to drug resistance in Mycobacterium tuberculosis in Latvia. J Clin Microbiol. 2002, 40: 3789-3792. 10.1128/JCM.40.10.3789-3792.2002.CrossRefPubMedPubMedCentral Tracevska T, Jansone I, Broka L, Marga O, Baumanis V: Mutations in the rpo B and katG genes leading to drug resistance in Mycobacterium tuberculosis in Latvia. J Clin Microbiol. 2002, 40: 3789-3792. 10.1128/JCM.40.10.3789-3792.2002.CrossRefPubMedPubMedCentral
18.
go back to reference Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F: Detection of Rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis. 2000, 4: 481-484.PubMed Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F: Detection of Rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis. 2000, 4: 481-484.PubMed
19.
go back to reference Watterson S, Wilson S, Yates M, Drobniewski F: Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol. 1998, 36: 1969-1973.PubMedPubMedCentral Watterson S, Wilson S, Yates M, Drobniewski F: Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol. 1998, 36: 1969-1973.PubMedPubMedCentral
20.
go back to reference Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003, 3: 25-. 10.1186/1471-2288-3-25. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003, 3: 25-. 10.1186/1471-2288-3-25.
21.
go back to reference Deeks JJ: Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001, 323: 157-162. 10.1136/bmj.323.7305.157.CrossRefPubMedPubMedCentral Deeks JJ: Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001, 323: 157-162. 10.1136/bmj.323.7305.157.CrossRefPubMedPubMedCentral
22.
go back to reference Pai M, McCulloch M, Enanoria W, Colford JM: Systematic reviews of diagnostic test evaluations: what's behind the scenes?. ACP Journal Club. 2004, 141: 11-A. Pai M, McCulloch M, Enanoria W, Colford JM: Systematic reviews of diagnostic test evaluations: what's behind the scenes?. ACP Journal Club. 2004, 141: 11-A.
24.
go back to reference Walter SD: Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002, 21: 1237-1256. 10.1002/sim.1099.CrossRefPubMed Walter SD: Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002, 21: 1237-1256. 10.1002/sim.1099.CrossRefPubMed
25.
go back to reference Moses LE, Shapiro D, Littenberg B: Combining independent studies of a diagnostic test into a summery ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993, 12: 1293-1316.CrossRefPubMed Moses LE, Shapiro D, Littenberg B: Combining independent studies of a diagnostic test into a summery ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993, 12: 1293-1316.CrossRefPubMed
26.
go back to reference Lijmer JG, Bossuyt PM, Heisterkamp SH: Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med. 2002, 21: 1525-1537. 10.1002/sim.1185.CrossRefPubMed Lijmer JG, Bossuyt PM, Heisterkamp SH: Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med. 2002, 21: 1525-1537. 10.1002/sim.1185.CrossRefPubMed
27.
go back to reference Morcillo N, Zumarraga M, Alito A, Dolmann A, Schouls L, Cataldi A, Kremer K, van Soolingen D: A low cost, home-made, reverse-line blot hybridization assay for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2002, 6: 1-7. Morcillo N, Zumarraga M, Alito A, Dolmann A, Schouls L, Cataldi A, Kremer K, van Soolingen D: A low cost, home-made, reverse-line blot hybridization assay for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2002, 6: 1-7.
Metadata
Title
A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis
Authors
Maureen Morgan
Shriprakash Kalantri
Laura Flores
Madhukar Pai
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2005
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-5-62

Other articles of this Issue 1/2005

BMC Infectious Diseases 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.